BioCryst to present new Orladeyo (berotralstat) data at annual scientific meeting of American College of Allergy, Asthma & Immunology
BioCryst Pharmaceuticals today announces that the company will present two abstracts on oral, once-daily Orladeyo (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) in patients 12 years and older at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).
The meeting will take place at the Anaheim Convention Center in Anaheim, Calif., from 9-13th November 2023.
The abstracts being presented are:
- Berotralstat Reduced Attack Rates in Patients with Hereditary Angioedema with Normal C1-Inhibitor: Real-World Outcomes; ePoster #P082; Friday, November 10, 5:30-5:45 p.m. PT; Monitor #13, Exhibit Hall
- Berotralstat Reduced Attack Rates Compared to Baseline in Patients with Hereditary Angioedema in APeX-S; ePoster #P064; Saturday, November 11, 12:05-12:20 p.m. PT; Monitor #12, Exhibit Hall
In addition to displaying in the exhibit hall at the noted times, ePosters will be accessible online and on demand to registered attendees on Thursday, November 9, beginning at 8:00am Pacific Time on ACAAI’s website.
(Source: BioCryst)
